EXPORT CITATION

Chapter-124 Management of Coronary Artery Disease in Diabetes Mellitus—Is It Different?

BOOK TITLE: CSI: Cardiology Update 2014

Author
1. Moorthy Asha
2. Kallarakkal Jain T
ISBN
9789351526186
DOI
10.5005/jp/books/12415_125
Edition
1/e
Publishing Year
2015
Pages
3
Author Affiliations
1. Sri Ramachandra University, Chennai, India, drashasrmc@yahoo.co.in, Sri Ramachandra University, Chennai, Tamil nadu, India, Ramachandran Medical College, Chennai, Tamil Nadu, India, GG Heart Institute, Chennai, Tamil Nadu, India, St Mary’s Hospital, Thodupuzha, Kerala, India, CG Heart Institute, Super-Speciality Hospitals, Chennai, Tamil Nadu, India, Cardiac Care Centre, Sri Ramachandra University, Chennai, Tamil Nadu, India, GG Multispeciality Hospital, Chennai, Tamil Nadu, India, SRM Institutes for Medical Science, Chennai, Tamil Nadu, India, SIMS Hospital, Chennai, Tamil Nadu, India, Sri Ramachandra University, Saveetha University, Chennai, Tamil Nadu, India
2. MBMM Hospital, Kochi, India, doctorjain1973@yahoo.com, St Mary’s Hospital, Thodupuzha, Kerala, India, Mar Baselios Medical Mission Hospital, Kochi, Kerala, India, Shree Narayana Institute of Medical Sciences, Kochi, Kerala, India
Chapter keywords
Cardiovascular diseases, coronary heart disease, acute coronary syndrome, Clopidogrel, OPTIMUS, Prasugrel, eptifibatide, target vessel revascularization

Abstract

Cardiovascular diseases comprising coronary heart disease and cerebrovascular diseases are the leading cause of death in people with diabetes. Three large prospective studies ACCORD, ADVANCE, VADT show that diabetes is a leading cause of adult-onset blindness, end-stage renal disease etc. worldwide and proper glycemic control reduces the microvascular complications. Medical management in acute coronary syndromes is necessary and consists of Antiplatelet Therapy, Percutaneous Coronary Interventions and Coronary Artery Bypass Surgery. There are three classes of antiplatelet agents such as: aspirin, adenosine diphosphate (ADP) P2Y12 receptor antagonists and glycoprotein (GP) IIb/IIIa inhibitors. Aspirin, Clopidogrel, Prasugrel and Ticagrelor and abciximab, eptifibatide, and tirofiban are some potent inhibitors approved for clinical use in the PCI. Percutaneous Coronary Interventions and Coronary Artery Bypass Surgery also discussed here.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved